UNASSIGNED: This meta-analysis was registered in INPLASY with the registration number INPLASY202360027. The electronic databases MedLine, EmBase, and the Cochrane library were systematically searched to identify eligible studies from their inception up to September 2023. The investigated outcomes included knee injury, secondary ACL, contralateral ACL injury, and graft rupture. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using the random-effects model.
UNASSIGNED: A total number of nine studies involving 1410 individuals were selected for the final quantitative analysis. We noted that passing RTS test was not associated with the risk of subsequent knee injury (OR: 0.95; 95% CI: 0.28-3.21; P = 0.929), secondary ACL injury (OR: 0.98; 95% CI: 0.55-1.75; P = 0.945), and contralateral ACL injury (OR: 1.53; 95% CI: 0.63-3.71; P = 0.347). However, the risk of graft rupture was significantly reduced (OR: 0.49; 95% CI: 0.33-0.75; P = 0.001).
UNASSIGNED: This study found that passing RTS test was not associated with the risk of subsequent knee injury, secondary ACL injury, and contralateral ACL injury, while it was associated with a lower risk of graft rupture. Thus, it is recommended that patients after ACLR pass an RTS test in clinical settings.
■该荟萃分析在INPLASY中注册,注册号为INPLASY202360027。电子数据库MedLine,Embase,和Cochrane图书馆进行了系统搜索,以确定从开始到2023年9月的合格研究。调查的结果包括膝关节损伤,辅助ACL,对侧ACL损伤,和移植物破裂。使用随机效应模型计算合并比值比(OR)和95%置信区间(CI)。
■总共选择了9项涉及1410名个体的研究进行最终定量分析。我们注意到通过RTS测试与后续膝关节损伤的风险无关(OR:0.95;95%CI:0.28-3.21;P=0.929)。继发性ACL损伤(OR:0.98;95%CI:0.55-1.75;P=0.945),和对侧ACL损伤(OR:1.53;95%CI:0.63-3.71;P=0.347)。然而,移植物破裂的风险显著降低(OR:0.49;95%CI:0.33-0.75;P=0.001).
■这项研究发现,通过RTS测试与随后膝盖受伤的风险无关,继发性ACL损伤,和对侧ACL损伤,虽然它与移植物破裂的风险较低有关。因此,建议ACLR后的患者在临床环境中通过RTS测试.